Dyadic International 2025 revenue falls, net loss widens

Overview

• US biotechnology firm's 2025 revenue fell yr/yr, driven by lower R&D and license revenue

• Net loss widened to $7.4 mln in 2025

Outlook

• Company did not provide specific financial guidance for the current or future periods in the press release

Result Drivers

• FEWER COLLABORATIONS - Co said 2025 revenue decline was mainly due to fewer active research and development collaborations

• LOWER MILESTONE PAYMENTS - Co attributed lower license and milestone revenue to reduced payments from partners

• INCREASED GRANT FUNDING - Higher grant revenue from Gates Foundation and CEPI partially offset declines in other revenue streams

Company press release: ID:nGNX8w3Mvk

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Dyadic International Inc is $7.00, about 728.9% above its March 24 closing price of $0.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.